Histone deacetylation contributes to low extracellular superoxide dismutase expression in human idiopathic pulmonary arterial hypertension

Eva Nozik-Grayck, Crystal Woods, Robert Stearman, Sujatha Venkataraman, Bradley S. Ferguson, Kalin Swain, Russell P. Bowler, Mark W. Geraci, Kaori Ihida-Stansbury, Kurt R. Stenmark, Timothy A. McKinsey, Frederick E. Domann

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Epigenetic mechanisms, including DNA methylation and histone acetylation, regulate gene expression in idiopathic pulmonary arterial hypertension (IPAH). These mechanisms can modulate expression of extracellular superoxide dismutase (SOD3 or EC-SOD), a key vascular antioxidant enzyme, and loss of vascular SOD3 worsens outcomes in animal models of pulmonary arterial hypertension. We hypothesized that SOD3 gene expression is decreased in patients with IPAH due to aberrant DNA methylation and/or histone deacetylation. We used lung tissue and pulmonary artery smooth muscle cells (PASMC) from subjects with IPAH at transplantation and from failed donors (FD). Lung SOD3 mRNA expression and activity was decreased in IPAH vs. FD. In contrast, mitochondrial SOD (Mn-SOD or SOD2) protein expression was unchanged and intracellular SOD activity was unchanged. Using bisulfite sequencing in genomic lung or PASMC DNA, we found the methylation status of the SOD3 promoter was similar between FD and IPAH. Furthermore, treatment with 5-aza-2=′ deoxycytidine did not increase PASMC SOD3 mRNA, suggesting DNA methylation was not responsible for PASMC SOD3 expression. Though total histone deacetylase (HDAC) activity, histone acetyltransferase (HAT) activity, acetylated histones, and acetylated SP1 were similar between IPAH and FD, treatment with two selective class I HDAC inhibitors increased SOD3 only in IPAH PASMC. Class I HDAC3 siRNA also increased SOD3 expression. Trichostatin A, a pan-HDAC inhibitor, decreased proliferation in IPAH, but not in FD PASMC. These data indicate that histone deacetylation, specifically via class I HDAC3, decreases SOD3 expression in PASMC and HDAC inhibitors may protect IPAH in part by increasing PASMC SOD3 expression.

Original languageEnglish (US)
Pages (from-to)L124-L134
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume311
Issue number1
DOIs
StatePublished - Jul 1 2016

Fingerprint

Histones
Superoxide Dismutase
Pulmonary Artery
Smooth Muscle Myocytes
DNA Methylation
Tissue Donors
Histone Deacetylase Inhibitors
decitabine
Lung
Blood Vessels
trichostatin A
Histone Acetyltransferases
Gene Expression
Familial Primary Pulmonary Hypertension
Messenger RNA
Histone Deacetylases
Acetylation
Pulmonary Hypertension
Epigenomics
Small Interfering RNA

Keywords

  • DNA methylation
  • Extracellular superoxide dismutase
  • Histone deacetylation
  • Idiopathic pulmonary arterial hypertension

ASJC Scopus subject areas

  • Physiology
  • Medicine(all)
  • Pulmonary and Respiratory Medicine
  • Cell Biology
  • Physiology (medical)

Cite this

Histone deacetylation contributes to low extracellular superoxide dismutase expression in human idiopathic pulmonary arterial hypertension. / Nozik-Grayck, Eva; Woods, Crystal; Stearman, Robert; Venkataraman, Sujatha; Ferguson, Bradley S.; Swain, Kalin; Bowler, Russell P.; Geraci, Mark W.; Ihida-Stansbury, Kaori; Stenmark, Kurt R.; McKinsey, Timothy A.; Domann, Frederick E.

In: American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 311, No. 1, 01.07.2016, p. L124-L134.

Research output: Contribution to journalArticle

Nozik-Grayck, E, Woods, C, Stearman, R, Venkataraman, S, Ferguson, BS, Swain, K, Bowler, RP, Geraci, MW, Ihida-Stansbury, K, Stenmark, KR, McKinsey, TA & Domann, FE 2016, 'Histone deacetylation contributes to low extracellular superoxide dismutase expression in human idiopathic pulmonary arterial hypertension', American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 311, no. 1, pp. L124-L134. https://doi.org/10.1152/ajplung.00263.2015
Nozik-Grayck, Eva ; Woods, Crystal ; Stearman, Robert ; Venkataraman, Sujatha ; Ferguson, Bradley S. ; Swain, Kalin ; Bowler, Russell P. ; Geraci, Mark W. ; Ihida-Stansbury, Kaori ; Stenmark, Kurt R. ; McKinsey, Timothy A. ; Domann, Frederick E. / Histone deacetylation contributes to low extracellular superoxide dismutase expression in human idiopathic pulmonary arterial hypertension. In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 2016 ; Vol. 311, No. 1. pp. L124-L134.
@article{c4ac04b140614be4a42fe8d4eef30bf4,
title = "Histone deacetylation contributes to low extracellular superoxide dismutase expression in human idiopathic pulmonary arterial hypertension",
abstract = "Epigenetic mechanisms, including DNA methylation and histone acetylation, regulate gene expression in idiopathic pulmonary arterial hypertension (IPAH). These mechanisms can modulate expression of extracellular superoxide dismutase (SOD3 or EC-SOD), a key vascular antioxidant enzyme, and loss of vascular SOD3 worsens outcomes in animal models of pulmonary arterial hypertension. We hypothesized that SOD3 gene expression is decreased in patients with IPAH due to aberrant DNA methylation and/or histone deacetylation. We used lung tissue and pulmonary artery smooth muscle cells (PASMC) from subjects with IPAH at transplantation and from failed donors (FD). Lung SOD3 mRNA expression and activity was decreased in IPAH vs. FD. In contrast, mitochondrial SOD (Mn-SOD or SOD2) protein expression was unchanged and intracellular SOD activity was unchanged. Using bisulfite sequencing in genomic lung or PASMC DNA, we found the methylation status of the SOD3 promoter was similar between FD and IPAH. Furthermore, treatment with 5-aza-2=′ deoxycytidine did not increase PASMC SOD3 mRNA, suggesting DNA methylation was not responsible for PASMC SOD3 expression. Though total histone deacetylase (HDAC) activity, histone acetyltransferase (HAT) activity, acetylated histones, and acetylated SP1 were similar between IPAH and FD, treatment with two selective class I HDAC inhibitors increased SOD3 only in IPAH PASMC. Class I HDAC3 siRNA also increased SOD3 expression. Trichostatin A, a pan-HDAC inhibitor, decreased proliferation in IPAH, but not in FD PASMC. These data indicate that histone deacetylation, specifically via class I HDAC3, decreases SOD3 expression in PASMC and HDAC inhibitors may protect IPAH in part by increasing PASMC SOD3 expression.",
keywords = "DNA methylation, Extracellular superoxide dismutase, Histone deacetylation, Idiopathic pulmonary arterial hypertension",
author = "Eva Nozik-Grayck and Crystal Woods and Robert Stearman and Sujatha Venkataraman and Ferguson, {Bradley S.} and Kalin Swain and Bowler, {Russell P.} and Geraci, {Mark W.} and Kaori Ihida-Stansbury and Stenmark, {Kurt R.} and McKinsey, {Timothy A.} and Domann, {Frederick E.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1152/ajplung.00263.2015",
language = "English (US)",
volume = "311",
pages = "L124--L134",
journal = "American Journal of Physiology",
issn = "0193-1857",
publisher = "American Physiological Society",
number = "1",

}

TY - JOUR

T1 - Histone deacetylation contributes to low extracellular superoxide dismutase expression in human idiopathic pulmonary arterial hypertension

AU - Nozik-Grayck, Eva

AU - Woods, Crystal

AU - Stearman, Robert

AU - Venkataraman, Sujatha

AU - Ferguson, Bradley S.

AU - Swain, Kalin

AU - Bowler, Russell P.

AU - Geraci, Mark W.

AU - Ihida-Stansbury, Kaori

AU - Stenmark, Kurt R.

AU - McKinsey, Timothy A.

AU - Domann, Frederick E.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Epigenetic mechanisms, including DNA methylation and histone acetylation, regulate gene expression in idiopathic pulmonary arterial hypertension (IPAH). These mechanisms can modulate expression of extracellular superoxide dismutase (SOD3 or EC-SOD), a key vascular antioxidant enzyme, and loss of vascular SOD3 worsens outcomes in animal models of pulmonary arterial hypertension. We hypothesized that SOD3 gene expression is decreased in patients with IPAH due to aberrant DNA methylation and/or histone deacetylation. We used lung tissue and pulmonary artery smooth muscle cells (PASMC) from subjects with IPAH at transplantation and from failed donors (FD). Lung SOD3 mRNA expression and activity was decreased in IPAH vs. FD. In contrast, mitochondrial SOD (Mn-SOD or SOD2) protein expression was unchanged and intracellular SOD activity was unchanged. Using bisulfite sequencing in genomic lung or PASMC DNA, we found the methylation status of the SOD3 promoter was similar between FD and IPAH. Furthermore, treatment with 5-aza-2=′ deoxycytidine did not increase PASMC SOD3 mRNA, suggesting DNA methylation was not responsible for PASMC SOD3 expression. Though total histone deacetylase (HDAC) activity, histone acetyltransferase (HAT) activity, acetylated histones, and acetylated SP1 were similar between IPAH and FD, treatment with two selective class I HDAC inhibitors increased SOD3 only in IPAH PASMC. Class I HDAC3 siRNA also increased SOD3 expression. Trichostatin A, a pan-HDAC inhibitor, decreased proliferation in IPAH, but not in FD PASMC. These data indicate that histone deacetylation, specifically via class I HDAC3, decreases SOD3 expression in PASMC and HDAC inhibitors may protect IPAH in part by increasing PASMC SOD3 expression.

AB - Epigenetic mechanisms, including DNA methylation and histone acetylation, regulate gene expression in idiopathic pulmonary arterial hypertension (IPAH). These mechanisms can modulate expression of extracellular superoxide dismutase (SOD3 or EC-SOD), a key vascular antioxidant enzyme, and loss of vascular SOD3 worsens outcomes in animal models of pulmonary arterial hypertension. We hypothesized that SOD3 gene expression is decreased in patients with IPAH due to aberrant DNA methylation and/or histone deacetylation. We used lung tissue and pulmonary artery smooth muscle cells (PASMC) from subjects with IPAH at transplantation and from failed donors (FD). Lung SOD3 mRNA expression and activity was decreased in IPAH vs. FD. In contrast, mitochondrial SOD (Mn-SOD or SOD2) protein expression was unchanged and intracellular SOD activity was unchanged. Using bisulfite sequencing in genomic lung or PASMC DNA, we found the methylation status of the SOD3 promoter was similar between FD and IPAH. Furthermore, treatment with 5-aza-2=′ deoxycytidine did not increase PASMC SOD3 mRNA, suggesting DNA methylation was not responsible for PASMC SOD3 expression. Though total histone deacetylase (HDAC) activity, histone acetyltransferase (HAT) activity, acetylated histones, and acetylated SP1 were similar between IPAH and FD, treatment with two selective class I HDAC inhibitors increased SOD3 only in IPAH PASMC. Class I HDAC3 siRNA also increased SOD3 expression. Trichostatin A, a pan-HDAC inhibitor, decreased proliferation in IPAH, but not in FD PASMC. These data indicate that histone deacetylation, specifically via class I HDAC3, decreases SOD3 expression in PASMC and HDAC inhibitors may protect IPAH in part by increasing PASMC SOD3 expression.

KW - DNA methylation

KW - Extracellular superoxide dismutase

KW - Histone deacetylation

KW - Idiopathic pulmonary arterial hypertension

UR - http://www.scopus.com/inward/record.url?scp=84982177978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982177978&partnerID=8YFLogxK

U2 - 10.1152/ajplung.00263.2015

DO - 10.1152/ajplung.00263.2015

M3 - Article

C2 - 27233998

AN - SCOPUS:84982177978

VL - 311

SP - L124-L134

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0193-1857

IS - 1

ER -